Compare Incyte Corporation (INCY) vs Sezzle Inc (SEZL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Sezzle Inc — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while Sezzle Inc trades at $173.8 (market cap $5.78B). The key difference: Incyte Corporation is far larger — about 4× Sezzle Inc's market cap. Which is the better fit depends on your goals.
| INCY | SEZL | |
|---|---|---|
Market Cap | $23.11B | $5.78B |
Sector | Health | Technology |
52-Week High | $118.52 | $188.55 |
52-Week Low | $67.38 | $50.97 |
Enterprise Value | $19.13B | $5.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Sezzle (SEZL) trades at $171.76, down 1.67% today but maintaining strong momentum with consistent earnings beats and bullish technical indicators. The stock shows robust fundamentals with 30.83% net income margin and 91.95% ROE, though valuations remain elevated at P/E 41.72. Recent news highlights product expansion and strong Q1 2026 results, with the company scheduled to report Q2 earnings on August 6, 2026.
Outlook remains positive given earnings momentum and analyst consensus, but high valuation multiples and competitive fintech landscape pose risks. The stock trades above the $162 consensus target, suggesting near-term consolidation potential before potential upward revisions post-earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →
